nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma
|
Arora, Mili |
|
2016 |
|
4 |
p. 209-221 |
artikel |
2 |
Bortezomib for the treatment of mantle cell lymphoma: an update
|
Hambley, Bryan |
|
2016 |
|
4 |
p. 196-208 |
artikel |
3 |
Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
|
Aalipour, Amin |
|
2014 |
|
4 |
p. 121-133 |
artikel |
4 |
Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant
|
Allen, Joshua |
|
2018 |
|
4 |
p. 81-87 |
artikel |
5 |
Editorial
|
Mauro, Michael J. |
|
2011 |
|
4 |
p. 201-201 |
artikel |
6 |
Editorial
|
Mauro, Michael J. |
|
2012 |
|
4 |
p. 197-198 |
artikel |
7 |
Editorial
|
Gotlib, Jason |
|
2013 |
|
4 |
p. 235-236 |
artikel |
8 |
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
|
Magen, Hila |
|
2016 |
|
4 |
p. 187-195 |
artikel |
9 |
Experience with ruxolitinib in the treatment of polycythaemia vera
|
Alimam, Samah |
|
2017 |
|
4 |
p. 139-151 |
artikel |
10 |
Experimental approaches in the treatment of multiple myeloma
|
Khan, Saad A. |
|
2011 |
|
4 |
p. 213-230 |
artikel |
11 |
Genetic predispositions to childhood leukemia
|
Stieglitz, Elliot |
|
2013 |
|
4 |
p. 270-290 |
artikel |
12 |
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
|
Castillo, Jorge J. |
|
2016 |
|
4 |
p. 179-186 |
artikel |
13 |
Inherited predisposition to multiple myeloma
|
Koura, Divya T. |
|
2013 |
|
4 |
p. 291-297 |
artikel |
14 |
Inherited predisposition to myeloproliferative neoplasms
|
Jones, Amy V. |
|
2013 |
|
4 |
p. 237-253 |
artikel |
15 |
Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future
|
Brown, Jennifer R. |
|
2013 |
|
4 |
p. 298-308 |
artikel |
16 |
Invasive fungal infections in acute leukemia
|
Bhatt, Vijaya R. |
|
2011 |
|
4 |
p. 231-247 |
artikel |
17 |
JAK inhibitors and other novel agents in myeloproliferative neoplasms: are we hitting the target?
|
Kucine, Nicole |
|
2011 |
|
4 |
p. 203-211 |
artikel |
18 |
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia
|
Schnaiter, Andrea |
|
2011 |
|
4 |
p. 249-265 |
artikel |
19 |
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data
|
Frustaci, Anna Maria |
|
2016 |
|
4 |
p. 222-230 |
artikel |
20 |
Pembrolizumab and its role in relapsed/refractory classical Hodgkin’s lymphoma: evidence to date and clinical utility
|
Shindiapina, Polina |
|
2018 |
|
4 |
p. 89-105 |
artikel |
21 |
Point-of-care ultrasonography (POCUS) in hemophilia A: a commentary on current status and its potential role for improving prophylaxis management in severe hemophilia A
|
Acharya, Suchitra S. |
|
2017 |
|
4 |
p. 153-156 |
artikel |
22 |
Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations
|
Ai, Jing |
|
2014 |
|
4 |
p. 107-120 |
artikel |
23 |
Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma
|
Abuodeh, Yazan |
|
2017 |
|
4 |
p. 129-138 |
artikel |
24 |
Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia
|
Bakchoul, Tamam |
|
2012 |
|
4 |
p. 237-251 |
artikel |
25 |
Recognizing familial myeloid leukemia in adults
|
Nickels, Eric M. |
|
2013 |
|
4 |
p. 254-269 |
artikel |
26 |
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
|
Vaklavas, Christos |
|
2012 |
|
4 |
p. 209-225 |
artikel |
27 |
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease
|
Richardson, Paul G. |
|
2012 |
|
4 |
p. 253-265 |
artikel |
28 |
Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia
|
Dyer, Martin J.S. |
|
2012 |
|
4 |
p. 199-207 |
artikel |
29 |
Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
|
Marchi, Enrica |
|
2012 |
|
4 |
p. 227-235 |
artikel |
30 |
The bone marrow microenvironment in Waldenstrom macroglobulinemia
|
Ghobrial, Irene M. |
|
2011 |
|
4 |
p. 267-272 |
artikel |
31 |
Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia
|
Wiedower, Eric |
|
2016 |
|
4 |
p. 231-232 |
artikel |